What happened to the CSL share price in May?

We look at what might have helped the biotech giant to outperform this month.

| More on:
Two happy scientists analysing test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price has outperformed this month, sliding 0.03% to trade at $273.22
  • That's despite the company releasing news of delays facing its Vifor Pharma acquisition
  • Though, it did update the market on its plasma collection business' COVID-19 recovery amid positive broker sentiment

The CSL Limited (ASX: CSL) share price has outperformed this month despite the company releasing potentially disappointing news.

The biotechnology stock has slipped 0.03% since the end of April. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has fallen 2.22%.

At the time of writing, the CSL share price is $273.22.

Let’s take a look at all the market has heard from the company this month.

What’s been going on with CSL this month?

The CSL share price has seemingly shrugged off the downturn spurred by a delay to the company’s $17.2 billion acquisition earlier this month.

The biotech giant announced its planned takeover of Vifor Pharma had hit a hurdle on 12 May.

Regulatory approvals are expected to drag the process out for a few months longer than was previously planned.

The news dragged the CSL share price 1.8% lower. Though, it lifted another 3.3% the following day.

The news also wasn’t enough to throw the stock off the course of the S&P/ASX 200 Health Care Index (ASX: XHJ).

TradingView Chart

As the above chart shows, CSL shares – represented in orange – have been trading closely in line with the company’s sector – represented in teal – over the last month.

Meanwhile, the ASX 200 – represented in blue – has been underperforming both.

There were a number of other happenings that might have bolstered market sentiment in CSL’s stock this month.

The company announced its plasma collections had reached pre-pandemic levels in early May.

Additionally, plenty of brokers are bullish on CSL’s stock. Notably, Citi slapped it with a $335 price target and Bell Potter expects big things to come.

CSL share price snapshot

While CSL’s stock has outperformed over the last month, it’s struggled over the longer term.

The company’s shares have slipped 8% year to date. They have also fallen 6% since this time last year.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Up 50% in a month: Why all these fundies predict more greatness for the Telix Pharmaceuticals share price

Several professional fund managers say the Telix Pharmaceuticals share price is on a growth trajectory. Here's why.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Dividend Investing

Medibank shares are currently trading on a 4% dividend yield. How does this compare to NIB?

Medibank vs. NIB... who wins when it comes to dividends?

Read more »

Two healthcare workers, a male doctor in the background with a woman in scrubs in the foreground,, smile towards the camera against a plain backdrop.
Broker Notes

5 reasons to buy this ASX healthcare share: Goldman Sachs

This could be the healthcare share to buy right now...

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Up 8% in July, is there more upside in the CSL share price this earnings season?

CSL is forecast to benefit from an improved outlook for plasma collections.

Read more »

A dollar sign embedded in ice, indicating a share price freeze or trading halt
Healthcare Shares

Why is the Mesoblast share price on ice today?

Mesoblast is another share placed on pause today.

Read more »

Woman holding out her hand, symbolising a trading halt.
Healthcare Shares

Medical Developments share price halted amid ‘significant near-term opportunities’

The company seeks to raise additional capital.

Read more »

A woman stretches her arms into the sky as she rises above the crowd.
Healthcare Shares

Up 22% in a month, can the Imugene share price extend its rally?

Imugene extends its gains today.

Read more »

Doctor reading a file
Healthcare Shares

What’s been impacting the Ramsay Health share price this week?

The hospital operator has decided to go its own way...

Read more »